TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9052519

Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (4-ASA) 6 g per day for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4-ASA
Number of subjects: 30
Study: 8419226

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) transdermally
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 57
Study: 3948539

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ampicillin plus netilmicin
Number of subjects: 59
Study: 30840567

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 0
Study: 27845482

Group type: EXPERIMENTAL
Intervention: Intervention group using games (cards and board games) and physical activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 24231655

Group type: EXPERIMENTAL
Intervention: Exergame training (24 1-hr sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 22286156

Group type: EXPERIMENTAL
Intervention: RV apical (RV‐A)
Number of subjects: 85

Group type: COMPARATOR
Intervention: RV high posterior septal (RV‐HS)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Concordant LV leads
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Concordant LV lead
Number of subjects: 85
Study: 20622139

Group type: EXPERIMENTAL
Intervention: Protein after exercise (PRO)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Carbohydrate after exercise (CHO)
Number of subjects: 2
Study: 19112513

Group type: EXPERIMENTAL
Intervention: 30 microg HA with aluminium hydroxide adjuvant (30 microg+Al)
Number of subjects: 240

Group type: COMPARATOR
Intervention: 7.5 microg HA without adjuvant
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 15 microg HA with aluminium hydroxide adjuvant (half dose)
Number of subjects: 240

Group type: COMPARATOR
Intervention: 3.8 microg HA without adjuvant (half dose)
Number of subjects: 240
Study: 11176812

Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 302
Study: 10342944

Group type: EXPERIMENTAL
Intervention: Oral cefpodoxime
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10-day course of penicillin V
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxicillin + clavulanate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefpodoxime
Number of subjects: 0
Study: 8199153

Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone (BIO‐OSS) placement in periapical defects
Number of subjects: 0
Study: 3239464

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 68

Group type: COMPARATOR
Intervention: No training
Number of subjects: 68
Study: 31159778

Group type: EXPERIMENTAL
Intervention: CHAP-P intervention (community-based health promotion sessions)
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Control group (random sample of community residents)
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: CHAP-P intervention
Number of subjects: 2600
Study: 28141699

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 91
Study: 26875271

Group type: EXPERIMENTAL
Intervention: Individualized reference model of sagittal curves and navigation templates of pedicle screw (trial group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional pedicle screw internal fixation by fluoroscopy assistant (control group)
Number of subjects: 42
Study: 23193200

Group type: EXPERIMENTAL
Intervention: Two-thumb (TT) technique
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Two-finger (TF) technique
Number of subjects: 22

Group type: COMPARATOR
Intervention: Overall compliance for both techniques
Number of subjects: 22
Study: 21738078

Group type: COMPARATOR
Intervention: Moderate to severe pelvic organ prolapse (any type)
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Moderate to severe rectocele
Number of subjects: 1192
Study: 18923027

Group type: EXPERIMENTAL
Intervention: Naloxone (to block central opioid function)
Number of subjects: 0
Study: 16551761

Group type: EXPERIMENTAL
Intervention: Structured information exchange between social insurance physician and occupational physician.
Number of subjects: 1564

Group type: COMPARATOR
Intervention: Control group (no structured information exchange).
Number of subjects: 1564
Study: 12667165

Group type: EXPERIMENTAL
Intervention: CMI and tandospirone (T group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CMI and diazepam (D group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CMI alone (C group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: T group
Number of subjects: 36
Study: 10750252

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg once daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 11322266

Group type: EXPERIMENTAL
Intervention: Didanosine once daily (270 mg/m2/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Didanosine twice daily (270 mg/m2/day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Didanosine once daily
Number of subjects: 53

Group type: COMPARATOR
Intervention: Didanosine twice daily
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 53
Study: 1556423

Group type: EXPERIMENTAL
Intervention: Oxygen (2 L by nasal prongs)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (nasal prongs only)
Number of subjects: 94
Study: 30982348

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30020415

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention to prevent serious fall injuries
Number of subjects: 5342

Group type: COMPARATOR
Intervention: Central screening strategy (mail)
Number of subjects: 5342

Group type: COMPARATOR
Intervention: Clinic screening strategy
Number of subjects: 5342
Study: 26901519

Group type: EXPERIMENTAL
Intervention: Mobile Voluntary Counseling and Testing (MVCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community Mobilization (CM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-Test Support Services (PTSS)
Number of subjects: 0
Study: 24635120

Group type: EXPERIMENTAL
Intervention: VR graded exposure therapy (VR‐GET)
Number of subjects: 0
Study: 21083769

Group type: EXPERIMENTAL
Intervention: 1.8 g/day of Lippia citriodora extracts (PLX(®) -group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PLB-group)
Number of subjects: 15
Study: 20637826

Group type: EXPERIMENTAL
Intervention: Selective pressure impression technique
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Traditional pressure relief technique
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 66
Study: 18924048

Group type: EXPERIMENTAL
Intervention: Short-time NPO-group (STNPO-group) with unlimited intake of Pfrimmer Nutricia preOP up to 2 hours before surgery
Number of subjects: 42

Group type: COMPARATOR
Intervention: Long-time NPO-group (LTNPO-group) with nothing per mouth after midnight
Number of subjects: 42
Study: 16858168

Group type: EXPERIMENTAL
Intervention: Use of digoxin
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: NYHA class IH-IV
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate in mL/min/1.73 m(2)
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Pulmonary congestion by chest x-ray
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: NYHA class III-IV
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Use of ACE inhibitors
Number of subjects: 1926
Study: 12963590

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment plus routine pediatric care
Number of subjects: 57

Group type: COMPARATOR
Intervention: Routine pediatric care
Number of subjects: 57
Study: 10394475

Group type: EXPERIMENTAL
Intervention: Olanzapine (25 mg/day for 8 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Clozapine (693 mg/day for 8 weeks)
Number of subjects: 44
Study: 8646956

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS; 60 cm)
Number of subjects: 680306

Group type: EXPERIMENTAL
Intervention: Endoscopic polypectomy
Number of subjects: 680306

Group type: COMPARATOR
Intervention: Double-contrast barium enema (DCE)
Number of subjects: 680306

Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 680306
Study: 1643821

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 110
Study: 6147549

Group type: EXPERIMENTAL
Intervention: Plasma exchange (8 large-volume exchanges over 4 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Prednisolone only (0.3 mg/kg daily, increased weekly)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Plasma exchange group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Prednisolone only group
Number of subjects: 41
Study: 31449915

Group type: EXPERIMENTAL
Intervention: Macrolides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TLR3 agonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytokine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (healthy mucosal tissue)
Number of subjects: 0
Study: 29553081

Group type: EXPERIMENTAL
Intervention: 5% Lidocaine hydrochloride (LH) in rice nanogel
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20% Lidocaine hydrochloride (LH) in rice nanogel
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5% Prilocaine hydrochloride (PH) in rice nanogel
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20% Prilocaine hydrochloride (PH) in rice nanogel
Number of subjects: 100

Group type: COMPARATOR
Intervention: RNG base (placebo)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Commercial anesthetic gels
Number of subjects: 100
Study: 27036056

Group type: EXPERIMENTAL
Intervention: Internet Mindfulness Meditation Intervention (IMMI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Internet-based health-and-wellness education program (control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 21
Study: 24285122

Group type: EXPERIMENTAL
Intervention: CapsoCam capsule
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: PillCam SB2
Number of subjects: 73

Group type: COMPARATOR
Intervention: Both systems
Number of subjects: 73
Study: 22263855

Group type: EXPERIMENTAL
Intervention: Simulation group (n=40)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 81
Study: 19412831

Group type: EXPERIMENTAL
Intervention: 114 g SBC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 60 g SBC with 144 g cooked paddy‐rice
Number of subjects: 20

Group type: COMPARATOR
Intervention: 144 g cooked paddy‐rice
Number of subjects: 20
Study: 17618137

Group type: EXPERIMENTAL
Intervention: Tizanidine (4 mg in the evenings for the first 2 postoperative days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (antibiotic and anti-inflammatory medications only)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 15321438

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg (group O4, n = 23)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg (group O8, n = 25)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Saline placebo (group P, n = 25)
Number of subjects: 73
Study: 12243809

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, vinblastine, and mitomycin-C (later dropped) followed by surgery
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, vinblastine (without mitomycin-C) followed by radiation therapy (RT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Induction chemotherapy followed by surgery or RT
Number of subjects: 75

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Radiation therapy (RT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Induction chemotherapy only
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Number of subjects: 75

Group type: COMPARATOR
Intervention: Surgery vs. RT
Number of subjects: 75
Study: 9520189

Group type: EXPERIMENTAL
Intervention: 1-day contact lens (1-Day Acuvue)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 15-day contact lens (Acuvue)
Number of subjects: 16
Study: 8126533

Group type: EXPERIMENTAL
Intervention: Noninvasive blood pressure measurement using finger photoplethysmography
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intraarterial blood pressure measurement
Number of subjects: 27
Study: 2550402

Group type: EXPERIMENTAL
Intervention: 10 mg MK-906
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg MK-906
Number of subjects: 12
Study: 1098721

Group type: EXPERIMENTAL
Intervention: MOPP (mustine, vincristine, procarbazine, prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MOP (mustine, vincristine, procarbazine)
Number of subjects: 0
Study: 31588904

Group type: EXPERIMENTAL
Intervention: Forward lean condition
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Self-disclosure condition
Number of subjects: 181

Group type: COMPARATOR
Intervention: Voice pitch condition
Number of subjects: 181

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 181
Study: 28579236

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stent (BP-BES)
Number of subjects: 2707

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stent (DP-EES)
Number of subjects: 2707
Study: 25270679

Group type: EXPERIMENTAL
Intervention: THC/CBD oromucosal spray
Number of subjects: 380
Study: 23427960

Group type: EXPERIMENTAL
Intervention: Single incision laparoscopic cholecystectomy (SILC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Multiport laparoscopic cholecystectomy (LC)
Number of subjects: 20
Study: 21956711

Group type: EXPERIMENTAL
Intervention: Combined therapy with pioglitazone (45 mg/day) and exenatide (10 μg twice daily) for 12 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exendin-4 for 4 weeks in DIO mice
Number of subjects: 24
Study: 19930832

Group type: EXPERIMENTAL
Intervention: Monitoring analgesia and sedation
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: MAP >or= 60 mmHg
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: BG >or= 80 mg/dl
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Analgesia monitoring
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: PIP <or= 35 cmH(2)O
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: TV <or= 6 ml/kg
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Analgesia monitoring, sedation monitoring, MAP >or= 60 mmHg, BG >or= 80 mg/dl and <or= 130 mg/dl, PIP <or= 35 cmH(2)O, TV <or= 6 ml/kg
Number of subjects: 634
Study: 16496035

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 95
Study: 12502992

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of local anesthetic and opioid (n = 34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care analgesic regimen (intramuscular meperidine, n = 34)
Number of subjects: 68
Study: 10921442

Group type: EXPERIMENTAL
Intervention: Integrated intervention (local anaesthesia, sensory and procedural information, parental involvement)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No preparation (control group)
Number of subjects: 31
Study: 8699777

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (+500 mg of metamizol)
Number of subjects: 20
Study: 1355629

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6387207

Group type: EXPERIMENTAL
Intervention: 2-mg nicotine chewing gum
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 31570004

Group type: EXPERIMENTAL
Intervention: Eravacycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ertapenem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 0
Study: 31277102

Group type: EXPERIMENTAL
Intervention: Xiao'er Feire Kechuan Oral Solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Macrolide antibiotics (erythromycin and azithromycin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 30
Study: 28804935

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 72
Study: 26330437

Group type: EXPERIMENTAL
Intervention: Vitamin C 1000 mg plus Vitamin E 1000 IU
Number of subjects: 0
Study: 23676961

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (Group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: General anesthesia (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of epidural and general anesthesia (Group C)
Number of subjects: 45
Study: 21886816

Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: HAART
Number of subjects: 80
Study: 17492378

Group type: EXPERIMENTAL
Intervention: CK19 mRNA positive status
Number of subjects: 195

Group type: COMPARATOR
Intervention: CK19 mRNA negative status
Number of subjects: 195
Study: 16606934

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (daily or biweekly injections)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (10 patients from another trial)
Number of subjects: 30
Study: 12860359

Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 24
Study: 11246616

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg orally) followed by octreotide (100 microg subcutaneously)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Octreotide (100 microg subcutaneously)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg subcutaneously) in patients receiving beta-blockers
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups after meal
Number of subjects: 15
Study: 9101010

Group type: EXPERIMENTAL
Intervention: Metformin with insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 0
Study: 8287573

Group type: EXPERIMENTAL
Intervention: Oestrogen replacement therapy (oestradiol valerate 2 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 3449561

Group type: EXPERIMENTAL
Intervention: Oral solution of vancomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semi-solid matrix capsules of vancomycin
Number of subjects: 0
Study: 29076376

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg and metformin 500 mg
Number of subjects: 202

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg
Number of subjects: 202
Study: 27210844

Group type: EXPERIMENTAL
Intervention: Mulligan's bent leg raise (BLR)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Butler's neural tissue mobilization (NTM)
Number of subjects: 31
Study: 24903122

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) for skin cancer treatment options and value clarification activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no DA experience)
Number of subjects: 0
Study: 23470322

Group type: EXPERIMENTAL
Intervention: Internet intervention program for physical activity
Number of subjects: 368

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 368
Study: 21178836

Group type: EXPERIMENTAL
Intervention: Comic Book of the Back (intervention group)
Number of subjects: 497

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 497
Study: 18316673

Group type: EXPERIMENTAL
Intervention: Active rTMS (TCD-12K)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Active rTMS (TCD-18K)
Number of subjects: 92
Study: 16816509

Group type: EXPERIMENTAL
Intervention: Plasma derived hepatitis B vaccine (pre‐S and S antigens)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (S antigen only)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 0, 1, 6 schedule
Number of subjects: 159

Group type: COMPARATOR
Intervention: 0, 1, 2 schedule
Number of subjects: 159
Study: 14627860

Group type: EXPERIMENTAL
Intervention: 644 mg/d DT56a
Number of subjects: 98

Group type: COMPARATOR
Intervention: 344 mg/d DT56a supplemented with calcium
Number of subjects: 98
Study: 10746534

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%-Mepivacaine 2%
Number of subjects: 2000
Study: 9111487

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with standardized allergen extracts
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (age-matched, monosensitized to HDM)
Number of subjects: 22
Study: 1587966

Group type: EXPERIMENTAL
Intervention: IV omeprazole 40 mg over 2.5 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IV omeprazole 80 mg over 5 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: IV placebo over 2.5 min
Number of subjects: 8
Study: 2941404

Group type: EXPERIMENTAL
Intervention: Teicoplanin 200 mg intramuscularly
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amoxycillin 3 g orally
Number of subjects: 30

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 30